FDA Finds No Heart Attack Risk With HIV Drug
March 2, 2011
Food and Drug Administration officials said Tuesday that a data review of the AIDS drug abacavir revealed no greater risk of heart attacks than other HIV medicines. Doctors should continue to prescribe abacavir as directed, the agency said. FDA's analysis included 26 clinical trials and began in 2008 after studies showed conflicting information about a possible link to heart attacks. Abacavir, a nucleoside reverse transcriptase inhibitor, is in the combination treatments Ziagen, Trizivir, and Epzicom.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)